CN102164894A - 前列腺素d2受体的杂芳基拮抗剂 - Google Patents

前列腺素d2受体的杂芳基拮抗剂 Download PDF

Info

Publication number
CN102164894A
CN102164894A CN2009801381671A CN200980138167A CN102164894A CN 102164894 A CN102164894 A CN 102164894A CN 2009801381671 A CN2009801381671 A CN 2009801381671A CN 200980138167 A CN200980138167 A CN 200980138167A CN 102164894 A CN102164894 A CN 102164894A
Authority
CN
China
Prior art keywords
compound
phenyl
pyridin
methyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801381671A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·霍华德·哈钦森
布赖恩·安德鲁·斯特恩斯
尼古拉斯·西蒙·斯托克
颜·品·张
杰弗里·罗杰·罗普
德博拉·沃尔科茨
吉尔·梅利莎·斯科特
蒂莫西·帕尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amira Pharmaceuticals Inc
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of CN102164894A publication Critical patent/CN102164894A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801381671A 2008-09-29 2009-09-28 前列腺素d2受体的杂芳基拮抗剂 Pending CN102164894A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10107408P 2008-09-29 2008-09-29
US61/101,074 2008-09-29
PCT/US2009/058655 WO2010037054A2 (en) 2008-09-29 2009-09-28 Heteroaryl antagonists of prostaglandin d2 receptors

Publications (1)

Publication Number Publication Date
CN102164894A true CN102164894A (zh) 2011-08-24

Family

ID=41327552

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801381671A Pending CN102164894A (zh) 2008-09-29 2009-09-28 前列腺素d2受体的杂芳基拮抗剂

Country Status (11)

Country Link
US (2) US8049015B2 (enExample)
EP (1) EP2328869A4 (enExample)
JP (1) JP2012504141A (enExample)
CN (1) CN102164894A (enExample)
AR (1) AR073319A1 (enExample)
CA (1) CA2737739C (enExample)
GB (1) GB2463788B (enExample)
PE (1) PE20100317A1 (enExample)
TW (1) TW201018465A (enExample)
UY (1) UY32152A (enExample)
WO (2) WO2010037059A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961732A (zh) * 2011-01-24 2015-10-07 勃林格殷格翰国际有限公司 作为crth2拮抗剂的吡唑化合物
CN109266735A (zh) * 2018-06-15 2019-01-25 天津医科大学 Crth2作为肺动脉高压免疫治疗药物靶标及其应用
CN109485664A (zh) * 2017-09-12 2019-03-19 北京凯莱天成医药科技有限公司 一种抗真菌药物他伐硼罗的制备工艺
CN110878043A (zh) * 2019-11-18 2020-03-13 南京哈柏医药科技有限公司 一种简便的6-甲氧基吡啶-3-甲醛的合成工艺

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98839C2 (en) * 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009102893A2 (en) * 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
WO2009145989A2 (en) * 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US8674040B2 (en) 2008-07-25 2014-03-18 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
US8710163B2 (en) 2008-07-25 2014-04-29 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
CN102596193A (zh) * 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗的皮肤调配物
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
EP2462110A4 (en) 2009-08-05 2013-04-03 Panmira Pharmaceuticals Llc DP2 ANTAGONIST AND USES THEREOF
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8623974B2 (en) 2011-03-25 2014-01-07 Exxonmobil Chemical Patents Inc. Branched vinyl terminated polymers and methods for production thereof
US8318998B2 (en) 2011-03-25 2012-11-27 Exxonmobil Chemical Patents Inc. Enhanced catalyst performance for production of vinyl terminated propylene and ethylene/propylene macromers
US8835563B2 (en) 2011-03-25 2014-09-16 Exxonmobil Chemical Patents Inc. Block copolymers from silylated vinyl terminated macromers
US8399724B2 (en) 2011-03-25 2013-03-19 Exxonmobil Chemical Patents Inc. Vinyl terminated higher olefin copolymers and methods to produce thereof
US8940839B2 (en) 2011-03-25 2015-01-27 Exxonmobil Chemical Patents Inc. Diblock copolymers prepared by cross metathesis
US8841397B2 (en) 2011-03-25 2014-09-23 Exxonmobil Chemical Patents Inc. Vinyl terminated higher olefin polymers and methods to produce thereof
AU2012243583B2 (en) 2011-04-12 2015-10-22 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for CETP inhibitor
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
US9102773B2 (en) 2013-02-06 2015-08-11 Exxonmobil Chemical Patents Inc. Process for controlling molecular weight of polyolefins prepared using pyridyl diamide catalyst systems
US9290519B2 (en) 2013-11-15 2016-03-22 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
US9260552B2 (en) 2013-11-15 2016-02-16 Exxonmobil Chemical Patents Inc. Process to produce polymers from pyridyldiamido transition metal complexes and use thereof
WO2015073157A1 (en) 2013-11-15 2015-05-21 Exxonmobil Chemical Patents Inc. Process to produce polymers from pyridyldiamido transition metal complexes and use thereof
US9315593B2 (en) 2013-11-15 2016-04-19 Exxonmobil Chemical Patents Inc. Catalyst systems comprising pyridyldiamido transition metal complexes and chain transfer agent and use thereof
US9315526B2 (en) 2014-03-03 2016-04-19 Exxonmobil Chemical Patents Inc. Pyridyldiamido transition metal complexes, production and use thereof
US9598444B2 (en) 2015-06-30 2017-03-21 Exxonmobil Chemical Patents Inc. Transition metal complexes of tridentate dianionic CNN ligands, production and use thereof
WO2017003565A1 (en) 2015-06-30 2017-01-05 Exxonmobil Chemical Patents Inc. Transition metal complexes of tridentate dianionic cnn ligands, production and use thereof
AR105711A1 (es) * 2015-08-17 2017-11-01 Japan Tobacco Inc Compuestos de hidroxitriazina y sus usos farmacéuticos
CN107922527A (zh) 2015-08-31 2018-04-17 埃克森美孚化学专利公司 用于聚烯烃反应的具有悬垂烯烃的铝烷基
US10618988B2 (en) 2015-08-31 2020-04-14 Exxonmobil Chemical Patents Inc. Branched propylene polymers produced via use of vinyl transfer agents and processes for production thereof
US10676547B2 (en) 2015-08-31 2020-06-09 Exxonmobil Chemical Patents Inc. Aluminum alkyls with pendant olefins on clays
US10829569B2 (en) 2015-08-31 2020-11-10 Exxonmobil Chemical Patents Inc. Polymers produced via use of vinyl transfer agents
US9982067B2 (en) 2015-09-24 2018-05-29 Exxonmobil Chemical Patents Inc. Polymerization process using pyridyldiamido compounds supported on organoaluminum treated layered silicate supports
US10562987B2 (en) 2016-06-30 2020-02-18 Exxonmobil Chemical Patents Inc. Polymers produced via use of quinolinyldiamido transition metal complexes and vinyl transfer agents
US10927196B2 (en) 2016-06-30 2021-02-23 Exxonmobil Chemical Patents Inc. Long chain branched polypropylene via polymerization with aluminum vinyl transfer agent
US10208140B2 (en) 2016-06-30 2019-02-19 Exxonmobil Chemical Patents Inc. Quinolinyldiamido transition metal complexes, production and use thereof
SG11201811335UA (en) 2016-06-30 2019-01-30 Exxonmobil Chemical Patents Inc Quinolinyldiamido transition metal complexes, production and use thereof
WO2018022249A1 (en) 2016-07-29 2018-02-01 Exxonmobil Chemical Patents Inc. Heterocyclic amido transition metal complexes, production and use thereof
US10150821B2 (en) 2016-07-29 2018-12-11 Exxonmobil Chemical Patents Inc. Heterocyclic amido transition metal complexes, production and use thereof
US10882932B2 (en) 2016-10-05 2021-01-05 Exxonmobil Chemical Patents Inc. Sterically hindered metallocenes, synthesis and use
US10626200B2 (en) 2017-02-28 2020-04-21 Exxonmobil Chemical Patents Inc. Branched EPDM polymers produced via use of vinyl transfer agents and processes for production thereof
WO2018160278A1 (en) 2017-03-01 2018-09-07 Exxonmobil Chemical Patents Inc. Branched ethylene copolymers produced via use of vinyl transfer agents and processes for production thereof
CN111094988A (zh) 2017-09-13 2020-05-01 普罗根尼蒂公司 先兆子痫生物标志物及相关系统和方法
US11578155B2 (en) 2018-03-08 2023-02-14 Exxonmobil Chemical Patents Inc. Ethylene-propylene linear copolymers as viscosity modifiers
CN112236505A (zh) 2018-03-08 2021-01-15 埃克森美孚化学专利公司 具有增强的燃料经济性的作为粘度改性剂的乙烯-丙烯支化共聚物
US20220289882A1 (en) 2019-08-27 2022-09-15 Chevron Oronite Company Llc Ethylene copolymers and use as viscosity modifiers
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033105A2 (en) * 2003-09-30 2005-04-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
US20080116172A1 (en) * 2006-11-22 2008-05-22 Clarkson University Method For One-To-One Polishing Of Silicon Nitride And Silicon Oxide

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239084A (en) 1990-06-29 1993-08-24 Hoffmann-La Roche Inc. Substituted aminoalkyl biphenyl compounds
US5827868A (en) 1991-10-07 1998-10-27 E. R. Squibb & Sons, Inc. Prostaglandin analogs
US5334598A (en) 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5565485A (en) 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5391566A (en) 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
DE19601782A1 (de) 1996-01-19 1997-07-24 Merck Patent Gmbh Chinolin-2-(1H)one
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
DE19937537A1 (de) 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate
DE60025368T2 (de) 1999-08-23 2006-09-14 Bml Inc. Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
ES2272712T3 (es) 2001-05-23 2007-05-01 Merck Frosst Canada Ltd. Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2.
EP1394147A4 (en) 2001-06-04 2007-10-24 Eisai R&D Man Co Ltd CARBOXYLENE DERIVATIVE AND A SALT OR AN ESTER CONTAINING MEDICINE
EP1408963A1 (en) 2001-07-09 2004-04-21 Axys Pharmaceuticals, Inc. 2- 5-(5-CARBAMIMIDOYL-1 i H /i -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
JP4484108B2 (ja) 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
CA2500083A1 (en) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
MXPA05004715A (es) 2002-10-30 2005-08-03 Merck Frosst Canada Inc Derivados de piridopirrolizina y piridoindolizina.
JP2004182657A (ja) 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
AU2003297398B2 (en) 2002-12-20 2009-09-24 Amgen Inc. Asthma and allergic inflammation modulators
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
AU2004266740B2 (en) 2003-08-21 2010-08-26 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
CA2542716A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
EP1688138A4 (en) 2003-11-26 2008-01-16 Takeda Pharmaceutical AGENT FOR REGULATING THE FUNCTION OF A RECEIVER
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
AU2005233160B2 (en) * 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors
NZ552187A (en) 2004-06-18 2010-08-27 Millennium Pharm Inc Thiophene-2-carboxamide derivatives
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
EP1773792A1 (en) 2004-07-30 2007-04-18 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
EP1805171A4 (en) 2004-09-21 2009-05-13 Wyeth Corp CRTH2 RECEPTOR ANTAGONISM DISPLAYING INDIGENOUS ACIDS AND APPLICATIONS THEREOF
KR20070115865A (ko) 2004-09-21 2007-12-06 아더시스 인코포레이티드 Ｃｒｔｈ2 수용체 길항작용을 나타내는 벤즈이미다졸아세트산 및 이의 용도
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006052798A2 (en) 2004-11-08 2006-05-18 Merck & Co., Inc. Method of treating pathological blushing
CA2587545C (en) * 2004-11-19 2013-10-22 Galderma Research & Development, S.N.C. Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions
AU2005308584A1 (en) 2004-11-23 2006-06-01 Pfizer Products Inc. Dibenzyl amine compounds and derivatives
PL1833791T3 (pl) 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
WO2006091496A2 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
EP1851202A1 (en) * 2005-02-25 2007-11-07 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
CA2619101A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
JP5155171B2 (ja) * 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
EP1963259B1 (en) 2005-12-15 2012-02-15 AstraZeneca AB Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
AU2007286829B2 (en) 2006-08-21 2013-05-02 Array Biopharma, Inc. 4-substituted phenoxyphenylacetic acid derivatives
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
WO2008082567A1 (en) 2006-12-29 2008-07-10 Merck & Co., Inc. Process for synthesizing a cetp inhibitor
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
UA99138C2 (ru) 2007-06-21 2012-07-25 Актимис Фармасьютикалз, Инк. Частичка антагониста crth2 (варианты)
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
US20100298368A1 (en) 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
US20100280049A1 (en) 2007-11-06 2010-11-04 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
WO2009089192A1 (en) 2008-01-07 2009-07-16 Ligand Pharmaceuticals Inc. 2-phenyl phenoxyacetic acids useful for treating inflammatory disorders
PT2250161E (pt) 2008-01-18 2014-01-21 Atopix Therapeutics Ltd Compostos tendo atividade antagonista de crth2
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
UA98839C2 (en) 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
WO2009145989A2 (en) 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
AU2009266793B2 (en) 2008-07-03 2012-12-20 Brickell Biotech, Inc. Antagonists of prostaglandin D2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
US20100173313A1 (en) 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
CN102596193A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗的皮肤调配物
EP2462110A4 (en) 2009-08-05 2013-04-03 Panmira Pharmaceuticals Llc DP2 ANTAGONIST AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033105A2 (en) * 2003-09-30 2005-04-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
US20080116172A1 (en) * 2006-11-22 2008-05-22 Clarkson University Method For One-To-One Polishing Of Silicon Nitride And Silicon Oxide

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961732A (zh) * 2011-01-24 2015-10-07 勃林格殷格翰国际有限公司 作为crth2拮抗剂的吡唑化合物
CN104961732B (zh) * 2011-01-24 2017-07-11 艾克提麦斯医药品有限公司 作为crth2拮抗剂的吡唑化合物
CN109485664A (zh) * 2017-09-12 2019-03-19 北京凯莱天成医药科技有限公司 一种抗真菌药物他伐硼罗的制备工艺
CN109485664B (zh) * 2017-09-12 2022-03-08 北京凯莱天成医药科技有限公司 一种抗真菌药物他伐硼罗的制备工艺
CN109266735A (zh) * 2018-06-15 2019-01-25 天津医科大学 Crth2作为肺动脉高压免疫治疗药物靶标及其应用
CN110878043A (zh) * 2019-11-18 2020-03-13 南京哈柏医药科技有限公司 一种简便的6-甲氧基吡啶-3-甲醛的合成工艺

Also Published As

Publication number Publication date
WO2010037059A2 (en) 2010-04-01
EP2328869A2 (en) 2011-06-08
WO2010037054A3 (en) 2010-07-08
US20100081673A1 (en) 2010-04-01
CA2737739C (en) 2013-09-24
UY32152A (es) 2010-04-30
US8049015B2 (en) 2011-11-01
WO2010037059A3 (en) 2010-07-22
WO2010037054A2 (en) 2010-04-01
GB2463788B (en) 2010-12-15
EP2328869A4 (en) 2013-01-09
CA2737739A1 (en) 2010-04-01
US20110312974A1 (en) 2011-12-22
JP2012504141A (ja) 2012-02-16
AR073319A1 (es) 2010-10-28
PE20100317A1 (es) 2010-05-18
GB0916810D0 (en) 2009-11-04
TW201018465A (en) 2010-05-16
GB2463788A (en) 2010-03-31

Similar Documents

Publication Publication Date Title
CA2737739C (en) Heteroaryl antagonists of prostaglandin d2 receptors
JP5531370B2 (ja) プロスタグランジンｄ２受容体のアンタゴニスト
US8034826B2 (en) Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors
TWI432402B (zh) 前列腺素ｄ2受體之ｎ，ｎ－二取代胺基烷基聯苯拮抗劑
TW200821286A (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
JP2011518130A (ja) プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
JP2011512359A (ja) プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
HUT64747A (en) Process for producing benzoic acid derivatives and pharmaceutical preparatives containing them
US5633258A (en) Pyridine compounds for treating leukotriene-related diseases
IE911938A1 (en) Amide linked pyridyl-benzoic acid derivatives for treating¹leukotriene-related diseases
HK1156301B (en) Antagonists of prostaglandin d2 receptors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: PAMELA PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: AMIRA PHARMACEUTICALS, INC.

Effective date: 20130704

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130704

Address after: American California

Applicant after: Amira Pharmaceuticals Inc.

Address before: American California

Applicant before: Amira Pharmaceuticals Inc.

AD01 Patent right deemed abandoned

Effective date of abandoning: 20110824

C20 Patent right or utility model deemed to be abandoned or is abandoned